tiprankstipranks
Addus Homecare (DE:A41)
FRANKFURT:A41
Germany Market
A41
Addus Homecare
RESEARCH TOOLSreports

Addus Homecare (A41) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

A41 Analyst Ratings

Strong Buy
13Ratings
Strong Buy
11 Buy
1 Hold
1 Sell
Based on 13 analysts giving stock ratings to
Addus
Homecare
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

A41 Stock 12 Month Forecast

Average Price Target

€114.59
▲(18.74% Upside)
Based on 13 Wall Street analysts offering 12 month price targets for Addus Homecare in the last 3 months. The average price target is €114.59 with a high forecast of €134.44 and a low forecast of €83.26. The average price target represents a 18.74% change from the last price of €96.50.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"76":"€76","135":"€135","90.75":"€90.8","105.5":"€105.5","120.25":"€120.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":134.43763024999998,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€134.44</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":114.58519166111108,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€114.59</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":83.26459679999999,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€83.26</span>\n  </div></div>","useHTML":true}}],"tickPositions":[76,90.75,105.5,120.25,135],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,100,102.64904848076922,105.29809696153846,107.94714544230769,110.59619392307692,113.24524240384615,115.89429088461537,118.54333936538461,121.19238784615384,123.84143632692306,126.4904848076923,129.1395332884615,131.78858176923075,{"y":134.43763024999998,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,100,101.12193782008546,102.24387564017094,103.3658134602564,104.48775128034187,105.60968910042735,106.73162692051281,107.85356474059827,108.97550256068374,110.09744038076921,111.21937820085468,112.34131602094016,113.46325384102562,{"y":114.58519166111108,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,100,98.71266129230769,97.42532258461539,96.13798387692307,94.85064516923077,93.56330646153846,92.27596775384615,90.98862904615385,89.70129033846153,88.41395163076922,87.12661292307692,85.8392742153846,84.5519355076923,{"y":83.26459679999999,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":91.5,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":96.5,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":98.5,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":104,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":92,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":86,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.5,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.5,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.5,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":86.5,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€134.44Average Price Target€114.59Lowest Price Target€83.26
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Stephens Analyst forecast on DE:A41
Unknown Analyst
Stephens
Not Ranked
Stephens
€117.96
Buy
22.24%
Upside
Reiterated
08/05/26
Addus Homecare (ADUS) Receives a Buy from Stephens
RBC Capital Analyst forecast on DE:A41
Ben Hendrix
RBC Capital
RBC Capital
€112.75→€116.22
Buy
20.44%
Upside
Reiterated
08/05/26
Addus HomeCare price target raised to $134 from $130 at RBC CapitalAddus HomeCare price target raised to $134 from $130 at RBC Capital
Truist Financial Analyst forecast on DE:A41
Clarke Murphy
Truist Financial
Truist Financial
€117.09
Buy
21.34%
Upside
Reiterated
08/05/26
Analysts' Top Healthcare Picks: Danaher (DHR), Vertex Pharmaceuticals (VRTX)
Bank of America Securities Analyst forecast on DE:A41
Joanna Gajuk
Bank of America Securities
Bank of America Securities
―
Buy
―
Reiterated
08/04/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
TD Cowen Analyst forecast on DE:A41
Ryan Langston
TD Cowen
TD Cowen
€113.62
Buy
17.74%
Upside
Assigned
08/04/26
Analysts Offer Insights on Healthcare Companies: Moleculin Biotech (NASDAQ: MBRX), Addus Homecare (NASDAQ: ADUS) and Rhythm Pharmaceuticals (NASDAQ: RYTM)
Barclays Analyst forecast on DE:A41
Andrew Mok CFA
Barclays
Barclays
€83.26
Sell
-13.72%
Downside
Reiterated
08/04/26
Barclays Remains a Sell on Addus Homecare (ADUS)
BMO Capital Analyst forecast on DE:A41
Sean Dodge
BMO Capital
BMO Capital
€95.41→€99.74
Hold
3.36%
Upside
Reiterated
08/04/26
Analysts Offer Insights on Healthcare Companies: TransMedics Group (NASDAQ: TMDX), Addus Homecare (NASDAQ: ADUS) and Henry Schein (NASDAQ: HSIC)
William Blair Analyst forecast on DE:A41
Jared Haase
William Blair
William Blair
―
Buy
―
Reiterated
08/03/26
Analysts Offer Insights on Healthcare Companies: Ocular Therapeutix (NASDAQ: OCUL) and Addus Homecare (NASDAQ: ADUS)
UBS Analyst forecast on DE:A41
A.J. Rice
UBS
UBS
€125.76
Buy
30.33%
Upside
Reiterated
06/24/26
Addus Homecare: Buy Rating Reiterated on Steady Volume Momentum, Acquisition Outperformance, and Double-Digit Growth Ambitions
KeyBanc Analyst forecast on DE:A41
Matthew Gillmor CFA
KeyBanc
KeyBanc
―
Buy
―
Reiterated
05/07/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Oppenheimer Analyst forecast on DE:A41
Michael Wiederhorn
Oppenheimer
Oppenheimer
€134.44
Buy
39.31%
Upside
Assigned
05/06/26
Oppenheimer Sticks to Their Buy Rating for Addus Homecare (ADUS)
Raymond James Analyst forecast on DE:A41
John Ransom
Raymond James
Raymond James
―
Buy
―
Reiterated
05/06/26
Analysts Offer Insights on Healthcare Companies: GoodRx Holdings (NASDAQ: GDRX), Compass Therapeutics (NASDAQ: CMPX) and Addus Homecare (NASDAQ: ADUS)
Citizens JMP Analyst forecast on DE:A41
Constantine Davides
Citizens JMP
Citizens JMP
€130.1→€123.16
Buy
27.63%
Upside
Reiterated
05/06/26
Addus HomeCare price target lowered to $142 from $150 at CitizensAddus HomeCare price target lowered to $142 from $150 at Citizens
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Stephens Analyst forecast on DE:A41
Unknown Analyst
Stephens
Not Ranked
Stephens
€117.96
Buy
22.24%
Upside
Reiterated
08/05/26
Addus Homecare (ADUS) Receives a Buy from Stephens
RBC Capital Analyst forecast on DE:A41
Ben Hendrix
RBC Capital
RBC Capital
€112.75→€116.22
Buy
20.44%
Upside
Reiterated
08/05/26
Addus HomeCare price target raised to $134 from $130 at RBC CapitalAddus HomeCare price target raised to $134 from $130 at RBC Capital
Truist Financial Analyst forecast on DE:A41
Clarke Murphy
Truist Financial
Truist Financial
€117.09
Buy
21.34%
Upside
Reiterated
08/05/26
Analysts' Top Healthcare Picks: Danaher (DHR), Vertex Pharmaceuticals (VRTX)
Bank of America Securities Analyst forecast on DE:A41
Joanna Gajuk
Bank of America Securities
Bank of America Securities
―
Buy
―
Reiterated
08/04/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
TD Cowen Analyst forecast on DE:A41
Ryan Langston
TD Cowen
TD Cowen
€113.62
Buy
17.74%
Upside
Assigned
08/04/26
Analysts Offer Insights on Healthcare Companies: Moleculin Biotech (NASDAQ: MBRX), Addus Homecare (NASDAQ: ADUS) and Rhythm Pharmaceuticals (NASDAQ: RYTM)
Barclays Analyst forecast on DE:A41
Andrew Mok CFA
Barclays
Barclays
€83.26
Sell
-13.72%
Downside
Reiterated
08/04/26
Barclays Remains a Sell on Addus Homecare (ADUS)
BMO Capital Analyst forecast on DE:A41
Sean Dodge
BMO Capital
BMO Capital
€95.41→€99.74
Hold
3.36%
Upside
Reiterated
08/04/26
Analysts Offer Insights on Healthcare Companies: TransMedics Group (NASDAQ: TMDX), Addus Homecare (NASDAQ: ADUS) and Henry Schein (NASDAQ: HSIC)
William Blair Analyst forecast on DE:A41
Jared Haase
William Blair
William Blair
―
Buy
―
Reiterated
08/03/26
Analysts Offer Insights on Healthcare Companies: Ocular Therapeutix (NASDAQ: OCUL) and Addus Homecare (NASDAQ: ADUS)
UBS Analyst forecast on DE:A41
A.J. Rice
UBS
UBS
€125.76
Buy
30.33%
Upside
Reiterated
06/24/26
Addus Homecare: Buy Rating Reiterated on Steady Volume Momentum, Acquisition Outperformance, and Double-Digit Growth Ambitions
KeyBanc Analyst forecast on DE:A41
Matthew Gillmor CFA
KeyBanc
KeyBanc
―
Buy
―
Reiterated
05/07/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Oppenheimer Analyst forecast on DE:A41
Michael Wiederhorn
Oppenheimer
Oppenheimer
€134.44
Buy
39.31%
Upside
Assigned
05/06/26
Oppenheimer Sticks to Their Buy Rating for Addus Homecare (ADUS)
Raymond James Analyst forecast on DE:A41
John Ransom
Raymond James
Raymond James
―
Buy
―
Reiterated
05/06/26
Analysts Offer Insights on Healthcare Companies: GoodRx Holdings (NASDAQ: GDRX), Compass Therapeutics (NASDAQ: CMPX) and Addus Homecare (NASDAQ: ADUS)
Citizens JMP Analyst forecast on DE:A41
Constantine Davides
Citizens JMP
Citizens JMP
€130.1→€123.16
Buy
27.63%
Upside
Reiterated
05/06/26
Addus HomeCare price target lowered to $142 from $150 at CitizensAddus HomeCare price target lowered to $142 from $150 at Citizens
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
MLYSMineralys Therapeutics, Inc.
ZURAZura Bio
TNYATenaya Therapeutics
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Addus Homecare

3 Months
Ryan LangstonTD Cowen
Success Rate
14/20 ratings generated profit
70%
Average Return
+5.85%
Copying Ryan Langston's trades and holding each position for 3 Months would result in 70.00% of your transactions generating a profit, with an average return of +5.85% per trade.
1 Year
Michael WiederhornOppenheimer
Success Rate
28/42 ratings generated profit
67%
Average Return
+17.62%
Copying Michael Wiederhorn's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +17.62% per trade.
2 Years
John RansomRaymond James
Success Rate
11/14 ratings generated profit
79%
Average Return
+21.35%
Copying John Ransom's trades and holding each position for 2 Years would result in 78.57% of your transactions generating a profit, with an average return of +21.35% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

A41 Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
1
2
2
1
0
Buy
10
10
11
11
8
Hold
1
1
1
1
1
Sell
2
3
2
3
2
Strong Sell
0
0
0
0
0
total
14
16
16
16
11
In the current month, A41 has received 8 Buy Ratings, 1 Hold Ratings, and 2 Sell Ratings. A41 average Analyst price target in the past 3 months is 114.59.
Each month's total comprises the sum of three months' worth of ratings.

A41 Financial Forecast

A41 Earnings Forecast

Next quarter’s earnings estimate for A41 is €1.55 with a range of €1.52 to €1.61. The previous quarter’s EPS was €1.50. A41 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.82% of the time in the same period. In the last calendar year A41 has Performed in-line its overall industry.
Next quarter’s earnings estimate for A41 is €1.55 with a range of €1.52 to €1.61. The previous quarter’s EPS was €1.50. A41 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.82% of the time in the same period. In the last calendar year A41 has Performed in-line its overall industry.

A41 Sales Forecast

Next quarter’s sales forecast for A41 is €336.71M with a range of €329.65M to €338.59M. The previous quarter’s sales results were €327.35M. A41 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.46% of the time in the same period. In the last calendar year A41 has Performed in-line its overall industry.
Next quarter’s sales forecast for A41 is €336.71M with a range of €329.65M to €338.59M. The previous quarter’s sales results were €327.35M. A41 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.46% of the time in the same period. In the last calendar year A41 has Performed in-line its overall industry.

A41 Stock Forecast FAQ

What is DE:A41’s average 12-month price target, according to analysts?
Based on analyst ratings, Addus Homecare’s 12-month average price target is 114.59.
    What is DE:A41’s upside potential, based on the analysts’ average price target?
    Addus Homecare has 18.74% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Addus Homecare a Buy, Sell or Hold?
          Addus Homecare has a consensus rating of Strong Buy, which is based on 11 buy ratings, 1 hold ratings and 1 sell ratings.
            What is Addus Homecare’s share price target?
            The average share price target for Addus Homecare is 114.59. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €134.44 ,and the lowest forecast is €83.26. The average share price target represents 18.74% Increase from the current price of €96.5.
              What do analysts say about Addus Homecare?
              Addus Homecare’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.
                How can I buy shares of Addus Homecare?
                To buy shares of DE:A41, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.